Innovative Technology Exogene leverages a proprietary AI platform for drug design, positioning it at the forefront of biotech innovation and providing opportunities to collaborate with pharmaceutical companies seeking advanced immune engager solutions.

Funding Growth With recent financing of 2 million USD, Exogene is well-positioned for expansion and increased R&D efforts, making it a strategic partner for investors or collaborators interested in early-stage biotech innovations.

Niche Market Focus Specializing in novel T cell therapies targeting solid tumors, Exogene offers targeted solutions to oncology firms and healthcare providers aiming to expand their cancer treatment portfolios.

Location Advantage Based in Oxford, a global hub for biotech research, Exogene can tap into a rich network of academic institutions and biotech clusters, facilitating partnerships and access to cutting-edge research collaborations.

Market Potential Given the global growth in immunotherapy and biotech, Exogene’s focus on immune engager drugs targeting peptide-HLA antigens presents significant opportunities for partnerships with larger biotech firms aiming to diversify their oncology pipelines.